Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$16.57 USD

16.57
8,793,432

+0.75 (4.74%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $16.55 -0.02 (-0.12%) 4:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome

Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.

Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Hims & Hers Health (HIMS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array

Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.

Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.

Earnings Estimates Rising for Hims & Hers Health (HIMS): Will It Gain?

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Henry Schein (HSIC) Extends Partnership With Special Olympics

Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Smart Beta ETF report for FYC

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.

QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus

QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.

Teleflex (TFX) Expands Vascular Access Portfolio With New Launch

Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.

Moumi Mondal headshot

Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings

Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.

Nalak Das headshot

5 Medical Info Systems Stocks to Buy for Stable Returns

We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stock to Buy for May 8th

HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.

New Strong Buy Stocks for May 8th

BRFS, GPS, GTN, HIMS and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2024.

Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top Estimates

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 150% and 2.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?

Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.

Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Brokers Suggest Investing in Hims & Hers Health (HIMS): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Hims & Hers Health (HIMS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.